EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2025
Summary Cystic Fibrosis (CF) is an inherited disorder that affects the cells that produce mucus, sweat and digestive juices, and also causes severe damage to the lungs, digestive system and other organs. These secreted fluids are normally thin and slippery. But in people with CF, a defective gene, known as the CFTR gene, causes the secretions to become sticky and thick. Instead of acting as a lubricant, the secretions plug up tubes, ducts and passageways (Mayo Clinic, 2016). In the lungs, the mucus clogs the airways and traps bacteria leading to infections, extensive lung damage and eventually, respiratory failure.
Key differences in the CF epidemiology between countries are influenced by genotype mutations, national screenings, and surveillance systems through national registries. The UK has the greatest prevalence proportion of CF, which may be the result of a strong presence of the mutations in the country (UK CFR, 2014). Reports indicate that British and French ancestries are the origins of CF-causing mutations (Physicians Committee for Responsible Medicine, 2008). National CF screenings are also imperative in detecting and capturing the true CF prevalence of a country.
According to the forecast adjusted for underestimation of registry data, the diagnosed incident cases of CF in the 7MM will decrease from 2,217 cases in 2015 to 2,074 cases in 2025, at an AGR of negative 0.64%. The US will have the highest number of diagnosed incident cases of CF among the 7MM throughout the forecast period, while Germany will have the lowest.
In the 7MM, based on registry data, our epidemiologists forecast that the diagnosed prevalent cases of CF will increase from 63,571 cases in 2015 to 73,368 cases in 2025, at an AGR of 1.54%. The US will have the highest number of diagnosed prevalent cases of CF among the 7MM throughout the forecast period, while Spain will have the lowest.
The report "EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2025" provides an overview of the risk factors, comorbidities, and the global and historical trends for CF in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Canada). It includes a 10-year epidemiological forecast for the diagnosed incident cases of CF, diagnosed prevalent cases of CF, and CF mortality based on county-specific registry data. Moreover this report provides the in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Scope - The Cystic Fibrosis (CF) EpiCast Report provides an overview of the risk factors and global trends of CF in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Canada). It includes a 10-year epidemiology forecast of diagnosed incident cases of CF, diagnosed prevalent cases of CF, and CF mortality segmented by sex in these seven markets. Diagnosed prevalent cases of CF are further segmented by age (starting from zero years of age and up to 85 years and older), specific mutation type, and chronic Methicillin-resistant Staphylococcus aureus (MRSA) infection.
- The CF epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy The CF EpiCast series will allow you to - - Develop business strategies by understanding the trends shaping and driving the global CF market.
- Quantify patient populations in the global CF market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CF therapeutics in each of the markets covered.
- Identify the percentage of CF diagnosed prevalent cases by age, sex, specific mutation type, and MRSA infection.
Our reports have been used by over 10K customers, including:
The ablation technology market is projected to reach USD 8.1 Billion by 2026 from USD 5.2 Billion in 2021, at a CAGR of 9.3% during the forecast period. The growing elderly population has also driven the incidence of target conditions and contributed to the demand for effective treatment. However, the reuse and reprocessing of devices in developed...
The Europe Surgical Robotic Systems Market would witness market growth of 20.5% CAGR during the forecast period (2020-2026). In recent years, developed robots permits doctors and surgeons to perform complicated surgeries and procedures with high adaptability and accuracy. Surgical robotic arms provide excellent control over tasks that...
Health is wealth: Demographic trends are expected to ultimately drive demand for primary care doctors Abstract Primary Care Doctors in Canada The Primary Care Doctors industry in Canada, which includes general practitioners who provide a comprehensive first point of contact and continued care, has exhibited...
A critical aspect of efficiency in healthcare organizations is asset management. Hospitals have thousands of assets to track and maintain, and failure of which results in increased waste and downtime, restricted patient flow, decreased quality of care, poor employee productivity, and financial losses.Hospitals are demanding more holistic solutions...
105 pages •
By The Business Research Company
• Feb 2017
Japan had the third highest GDP worth about $4.1 trillion accounting for 5.2% in $73 trillion global GDP. Japan is the third largest country in the healthcare services market and most healthcare spending is funded by the government through the National Health Insurance (NHI) or Employees’ Health Insurance programs. All residents in Japan...
103 pages •
By The Business Research Company
• Feb 2017
Africa is the second largest and the second most populous continent in the world. It has about 1.1 billion population and 15% of the world’s human population. The GCC countries rely heavily on the government funding for providing healthcare services. For instance, as per World Health Organization (WHO), the governments in Saudi Arabia and...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.